ClinicalTrials.gg
CompletedNCT05124925Updated Feb 2, 2026

Biopsy Based Study to Understand Mechanism of Action of Ianalumab in Salivary Glands and Explore Relationships With Clinical Assessments.

A Phase 2 interventional study of Ianalumab in Sjogren Syndrome, sponsored by Novartis Pharmaceuticals. Completed at 1 site in France. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Sjogren's Syndrome by Novartis — 2 open to participants now, 4 under way, 3 of them phase 3. Sjogren's Syndrome · Novartis.

Enrollment
13th of 14
21 · median 240
Started
2022
with 2 others
Phase 2
9 of 15
1 open now
Registered
9th of 15
by date

Among the 15 studies in Sjogren's Syndrome by Novartis, this one is the 13th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 2, and was the 9th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

2 of the 15 studies in Sjogren's Syndrome by Novartis are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Sjogren's Syndrome by Novartis, or all of them as a file.
02

Study summary

This study aims at elucidating the mechanism of action of ianalumab in salivary glands and explore relationships with clinical assessments

Read the detailed description

This is an open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome.

03

Conditions studied

  • Sjogren Syndrome

Keywords

  • Sjogren syndrome
  • VAY736
  • Ianalumab
  • dry eyes
  • dry mouth
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written must be obtained before any assessment is performed
  2. Male and female patients 18 years of age or older at Screening
  3. Confirmed Sjögren's syndrome according to the 2016 ACR/EULAR classification criteria
  4. Seropositive for anti-Ro/SSA antibodies
  5. Screening ESSPRI score ≥ 5
  6. Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Use of other drugs within 5 half-lives of enrollment or within 30 days whichever is longer, or longer if required by local regulations
  2. Presence of another rheumatic disease that is active and constitutes the primary illness
  3. Prior use of ianalumab
  4. History of receiving:

    o Any B-cell depleting therapies, other than ianalumab (e.g., rituximab, other anti-CD20 mAb, anti-CD22 mAb, or anti-CD52 mAb) administered within 36 weeks prior to randomization, or as long as B cell count is less than the lower limit of normal or baseline value prior to receipt of B cell-depleting therapy (whichever is lower)

  5. Current use of prednisone >10 mg/day [or equivalent other ] or dose change within 2 weeks prior to dosing
  6. Prior treatment with any of the following within 6 months of baseline

    1. CTLA4-Fc Ig (abatacept)
    2. Anti-TNF-α mAb
    3. Intravenous Ig
    4. Plasmapheresis
    5. i.v. or oral cyclophosphamide
    6. i.v. or oral cyclosporine A
    7. Patients taking either hydroxychloroquine more than 400 mg/day or methotrexate more than 25 mg weekly or leflunomide at not stable dose within 3 months prior to dosing.
    8. iscalimab (anti-0)
    9. belimumab (anti-BAFF mAb)
  7. Active viral, bacterial or other infections
  8. History of major organ, hematopoietic stem cell or bone marrow transplant
  9. History of to any of the study drugs or to drugs of similar chemical classes (e.g., mAb of IgG1 class) or to any of the constituents of the study drug formulation (sucrose, L-histidine hydrochloride/L-histidine, polysorbate 20)
  10. Required regular use of medications known to cause dry mouth/eyes as a regular and major side effect, and which have not been on a stable dose for at least 30 days prior to Screening, or any anticipated change in the treatment regimen during the course of the study
  11. Receipt of live/attenuated vaccine within a 4-week period prior to baseline
  12. History of primary or secondary immunodeficiency, or a positive (ELISA and Western blot) test result
  13. History of of any organ system (other than localized basal cell carcinoma of the skin, in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  14. History of head and neck radiation therapy or of having received radioactive iodine
  15. Any one of the following screening values of CBC laboratory values:

    • levels below 8.0 g/dL;
    • Total leukocyte count less than 2,000/μL;
    • \<50 x 109/L (if between 50 and 80, the PI should check that it is linked to Sjögren's syndrome and not to any other disease);
    • (ANC) \<1.0 x 109/L (one re-test is allowed during the screening period)
  16. Positive serology for surface antigen (HBsAg).

    Positive serology for hepatitis B core antibody (HBcAb), except if all 3 following criteria are met:

    • Hepatitis B (HBV) quantitative PCR for viral DNA is negative (i.e., \<10 IU)
    • Prophylactic treatment (with tenofovir or entecavir) initiated latest on day 1 and continued until 12 months after last treatment
    • Hepatitis B monitoring is implemented: HBsAg (and HBV DNA) tested every 4 weeks during treatment and at least every 12 weeks after end of treatment for the entire duration of the follow-up. Antiviral prophylaxis must be implemented while on study and up to 12 months after end of study treatment.
  17. Positive test result. Participants with a positive HCV antibody test should have HCV RNA levels measured. Participants with positive (detectable) HCV RNA should be excluded.
  18. Evidence of active tuberculosis (TB) infection (after anti-TB treatment, patients with history of or latent TB may become eligible according to national guidelines)
  19. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
  20. Women of (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of during dosing and for 6 months after stopping of investigational medication. Highly effective contraception methods include:

    • Total abstinence (when this is in line with the preferred and usual lifestyle of the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
    • Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or tubal ligation at least six weeks before taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
    • Male sterilization (at least 6 months prior to screening and confirmed as successful). For female patients in the study, the vasectomized male partner should be the sole partner for that patient
    • Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS) or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking investigational drug.

    Women are considered and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

    If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the form (ICF).

  21. Known to SonoVue (sulphur hexafluoride microbubbles) ultrasound contrast agent
  22. Participants not registered in the social security system
  23. Participants within the exclusion period of a preceding study
  24. Any surgical, medical (e.g. uncontrolled hypertension, heart failure or diabetes) psychiatric or additional physical condition that the investigator feels may jeopardize the patient in case of participation in this study
  25. People deprived of their liberty by a judicial or administrative decision (Article L1121-6 of the French Public Health Code)
  26. Screening Labial minor salivary gland (LMSG) lymphocyte focus score \< 0.3/4 mm2 or B/B+T ratio in the gland \< 0.2 (20%)
  27. Use of topical ocular prescription medications (excluding artificial tears, gels, lubricants) that have not been on a stable dose for at least 90 days prior to treatment, or any anticipated change in the treatment regimen during the course of the study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment Arm

    Ianalumab 300 mg subcutaneous monthly

    Biological: Ianalumab

Interventions

  • BiologicalIanalumab

    Ianalumab VAY736 150mg/1ml Solution for injection

06

What researchers measure

Primary outcomes

  1. Change in logarithm of salivary gland B/B+T cell ratio

    Change from baseline in logarithm of salivary gland B/B+T cell ratio at Week 25 (EOT)

    Time frame: Week 25

Secondary outcomes

  1. Number of participants with Adverse Events

    Occurrence of treatment emergent adverse events (both serious and non-serious) during the study and occurrence of treatment emergent abnormal vital signs, laboratory and ECG data.

    Time frame: 6 months treatment plus 2 years of follow-up

  2. Change from baseline in disease activity at salivary gland level by ultrasound imaging

    Changes in salivary gland tissue (parenchymal abnormalities, vascularization, perfusion and stiffness) by multimodal salivary gland ultrasound (SGUS) after treatment with ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  3. Incidence of ADA positive patients

    Serum anti-ianalumab antibody (ADA assay) and incidence of ADA positive patients as a measure of immunogenicity (IG) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  4. Change of salivary flow

    Defined as change in stimulated and unstimulated salivary flow from baseline

    Time frame: 6 months treatment plus 2 years of follow-up

  5. Serum ianalumab concentrations PK parameters Tmax

    To assess the pharmacokinetics (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  6. Serum ianalumab concentrations AUCinf

    To assess pharmacokinetics (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  7. Serum ianalumab concentrations C-max

    To assess pharmacokinetiks (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  8. Serum ianalumab concentrations PK parameters AUC from dosing to the time of the last measurable concentrations (AUClast)

    To assess the pharmacokinetics (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  9. Serum ianalumab concentrations PK parameters half life (T1/2)

    To assess the pharmacokinetics (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

  10. Serum ianalumab concentrations PK parameters AUC calculated to the end of a dosing interval (tau) at steady state

    To assess the pharmacokinetics (PK) of ianalumab

    Time frame: 6 months treatment plus 2 years of follow-up

07

Study locations

1 site
  • Novartis Investigative Site
    Brest, 29200, France
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Jun 2024, 22 months.

Of 26 phase 2 interventional studies under Sjogren's Syndrome, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's 22 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2021
First posted
Nov 18, 2021
StartActual
Jul 27, 2022
Primary completionActual
Jun 26, 2024
CompletionActual
Jan 5, 2026
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05124925
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Jul 27, 2022
Primary completion
Jun 26, 2024
Completion
Jan 5, 2026
Last update
Feb 2, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion